Cytek Biosciences, Inc. CTKB Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$74M— | -$66.54M— | —— | —— | —— | ||
| $7.57M+2.4% | $7.58M+5.1% | $7.54M+7.8% | $7.47M+8.2% | $7.39M+9.5% | ||
| $22.82M-18.0% | $24.59M-8.4% | $26.06M+2.1% | $27.48M+13.4% | $27.84M+21.1% | ||
| $33.71M+1,146% | $33.56M+1,263% | -$7.91M— | -$5.28M— | -$3.22M— | ||
| -$369K-239% | -$415K-655% | -$358K-588% | -$256K-334% | -$109K-102% | ||
| $872K— | $413K— | —— | —— | —— | ||
| —— | —— | —— | $8.48M+357% | $3.21M-65.9% | ||
| —— | —— | $5.3M+128% | -$483K+96.5% | -$8.48M+30.8% | ||
| —— | —— | $2.02M— | $3.66M— | —— | ||
| $2.2M— | $3.97M— | —— | —— | —— | ||
| -$1.34M-4,173% | $2.66M-5.4% | $47K-99.5% | $3.77M-43.2% | $33K-99.7% | ||
| —— | —— | —— | —— | —— | ||
| $3.43M-24.3% | $3.6M-3.6% | $3.26M— | $4.74M— | $4.54M— | ||
| $4.34M+22.9% | $4.4M+34.1% | $4.14M+29.9% | $3.95M+30.9% | $3.53M+12.2% | ||
| —— | —— | —— | —— | —— | ||
| -$7.41M-135% | -$4.79M-119% | -$2.03M-106% | $15.09M-2.2% | $21.3M— | ||
| $5.4M+41.9% | $4.08M+15.9% | $3.98M-3.7% | $4.33M-2.7% | $3.81M-19.2% | ||
| $139K-12.6% | $108K-49.1% | $85K-67.8% | $85K-74.0% | $159K-32.1% | ||
| $225K-29.9% | $252K-12.5% | $248K+156% | $268K+253% | $321K— | ||
| —— | —— | -$51.47M— | -$86.2M— | -$69.79M— | ||
| —— | —— | —— | $34.09M-25.4% | $32.25M— | ||
| $9.96M+186% | $5.58M+33.4% | $6.95M+397% | $4.87M+249% | $3.48M+150% | ||
| $4.1M+112% | $4.75M+752% | $1.94M+248% | $1.94M+249% | $1.94M+247% | ||
| $307K-44.0% | $325K-68.0% | $378K-69.0% | $388K-74.3% | $548K-69.1% | ||
| —— | —— | —— | -$29.87M+29.1% | -$28.98M+27.9% | ||
| $1.98M— | $109K— | $215K— | —— | —— | ||
| —— | —— | —— | -$102.45M— | -$73.84M— | ||
| -$1.59M-142% | $2.16M-43.6% | $1.93M-69.9% | $2.8M-50.8% | $3.83M-26.6% | ||
| —— | $0— | $0-100% | $0-100% | $0-100% | ||
| $3.43M-24.3% | $3.6M-3.6% | $3.26M— | $4.74M— | $4.54M— | ||
| -$1.16M+17.5% | -$1.13M-2.5% | -$1.96M— | -$1.62M— | -$1.4M— | ||
| —— | —— | —— | —— | —— | ||
| -$1.34M-4,173% | $2.66M-5.4% | $47K-99.5% | $3.77M-43.2% | $33K-99.7% | ||
| -$523K+92.9% | -$328K+95.4% | -$7.27M-1,035% | -$7.35M-716% | -$7.35M-651% | ||
| $1.58M+51.0% | $1.7M+3.5% | $735K-64.1% | $944K-50.6% | $1.05M-44.0% | ||
| —— | —— | —— | -$5.93M-11.1% | -$5.5M+12.4% | ||
| $4.34M+22.9% | $4.4M+34.1% | $4.14M+29.9% | $3.95M+30.9% | $3.53M+12.2% | ||
| —— | —— | —— | —— | —— | ||
| $872K— | $413K— | —— | —— | —— | ||
| $139K-12.6% | $108K-49.1% | $85K-67.8% | $85K-74.0% | $159K-32.1% | ||
| $225K-29.9% | $252K-12.5% | $248K+156% | $268K+253% | $321K— | ||
| $780K+45.8% | $670K+20.9% | $532K+1.1% | $507K-4.2% | $535K+4.9% | ||
| $4.1M+112% | $4.75M+752% | $1.94M+248% | $1.94M+249% | $1.94M+247% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $1K-99.8% | ||
| —— | —— | —— | $10.75M— | $3.32M— | ||
| -$1.59M-142% | $2.16M-43.6% | $1.93M-69.9% | $2.8M-50.8% | $3.83M-26.6% | ||
| —— | —— | —— | —— | —— | ||
| -$12.7M-173% | -$8.77M-140% | -$5.9M-120% | $10.87M-1.0% | $17.49M+947% | ||
| -$12.7M-173% | -$8.77M-140% | -$5.9M-120% | $10.87M-1.0% | $17.49M+947% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Cytek Biosciences, Inc. generate?
- Cytek Biosciences, Inc. (CTKB) generated -$7.4M in operating cash flow over the trailing twelve months.
- What is Cytek Biosciences, Inc.'s free cash flow?
- After $5.4M of capital expenditures, Cytek Biosciences, Inc.'s free cash flow was -$12.7M over the trailing twelve months, down 172.6% year over year.
- Where does Cytek Biosciences, Inc.'s cash flow data come from?
- Every line is extracted from Cytek Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
